Pharmaceuticals

Curaleaf Holdings, Inc.

Curaleaf Holdings, Inc. released FY2026 Q1 earnings on May 5 After-Market EST, actual revenue USD 324.23 M (forecast USD 317.05 M), actual EPS USD 0.0895

Curaleaf reports Q1 gross profit of $157.3 million

Curaleaf Holdings Schedules Annual and Special Meeting

Curaleaf Holdings Fully Acquires Four 20 Pharma

Curaleaf Completes Acquisition of Four 20 Pharma to Strengthen European Market Position

Curaleaf Holdings, Inc. to Release FY2026 Q1 Earnings on May 5 After-Market EST, Forecast Revenue USD 317.05 M

Curaleaf Holdings, Inc. Launches $83 Million Stock Repurchase Program

Curaleaf Inc stock price gaps down, revenue exceeds expectations

Curaleaf Holdings, Inc. released FY2025 Annual Earnings on February 27 After-Market (EST), Actual Revenue: USD 1.268 B (Forecast: USD 1.274 B), Actual EPS: USD -0.3587

Curaleaf Holdings, Inc. released FY2025 Q4 earnings on February 27 After-Market (EST), actual revenue USD 323.36 M (forecast USD 329.25 M), actual EPS USD -0.0904

Curaleaf Holdings, Inc. to Release FY2025 Q4 Earnings on February 26 After-Market EST, Forecast Revenue USD 328.27 M

Curaleaf Reports Strong Q4 Earnings and Plans to Exit Missouri Market

Curaleaf Holdings, Inc. released FY2025 Q3 earnings on November 6 After-Market (EST), actual revenue USD 320.24 M (forecast USD 316.87 M), actual EPS USD -0.0838

Curaleaf Holdings, Inc. released FY2025 9 Months Earnings on November 6 After-Market EST, with actual revenue of USD 944.77 M and EPS of USD -0.2695

Curaleaf Holdings, Inc. to Release FY2025 Q3 Earnings on November 5 After-Market EST, Forecast Revenue USD 317.11 M

Curaleaf Holdings, Inc. released FY2025 Q2 earnings on August 6 After-Market EST, actual revenue USD 314.52 M (forecast USD 313.92 M), actual EPS USD -0.0839

Curaleaf Holdings, Inc. released FY2025 Semi-Annual Earnings on August 6 After-Market EST, with actual revenue of USD 621.14 M and EPS of USD -0.1874

Curaleaf Holdings, Inc. to Release FY2025 Q2 Earnings on August 6 After-Market EST, Forecast Revenue USD 314.71 M

Curaleaf Holdings, Inc. released FY2025 Q1 earnings on May 8 After-Market EST, actual revenue USD 310.01 M (forecast USD 311.26 M), actual EPS USD -0.0998

Curaleaf Holdings, Inc. to release FY2025 Q1 earnings on May 8 After-Market EST, forecast revenue USD 314.07 M

OPTIMI HEALTH CORP

HCW Biologics

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

Micware

GCL Global

Silexion Therapeutics

Vida Global

MetaVia

MicroAlgo

Tradr 2X Long XNDU Daily ETF

TCNNF

TLRY

CURLF

CRON

GTBIF

MSOS

A new report from the Global Cannabis Network Collective and Whitney Economics highlights pricing compression as a key indicator of cannabis market maturity. It analyzes how expanding supply and evolving regulations impact pricing across emerging markets in Europe and Latin America. The report emphasizes that while initial market prices may be high, sustained downward pressure is common as markets mature. It also discusses the influence of regulatory frameworks and consumer behavior on pricing stability and operator profitability, providing insights for investors and policymakers.

prnewswire

Trulieve Cannabis Corp.

Tilray Brands

Aurora Cannabis

Canopy Growth

Cronos

Green Thumb Industries Inc.

AdvisorShares Pure US Cannabis ETF

Amplify Alternative Harvest ETF

07:05 ETNew Global Cannabis Report from GCNC and Whitney Economics Examines How Pricing Compression Reshapes Emerging Markets

Curaleaf Holdings, Inc. has announced the replacement of its independent auditor PKF O’Connor Davies with BDO USA, effective May 6, 2026. This change follows an unqualified audit history, indicating it is a routine governance step rather than a response to any accounting issues. The transition is documented under Canadian continuous disclosure rules, emphasizing continuity in financial oversight. Analysts rate CURA stock as a Buy with a C$5.00 price target, while Spark's AI Analyst gives it a Neutral rating due to ongoing net losses and leverage concerns.

Tip Ranks

Curaleaf Replaces PKF O’Connor Davies with BDO USA as Independent Auditor

Curaleaf Holdings has opened two new medical dispensaries in Jacksonville Beach and Fernandina Beach, increasing its Florida locations to 73 and total nationwide stores to 165. CEO Boris Jordan stated that this expansion aligns with their strategy to enhance their presence in the medical cannabis market, allowing for better localized product offerings and patient-focused services across Florida.

fidelity

Curaleaf Holdings Opens Two New Stores in Florida

Curaleaf Bolsters Florida Footprint with Two New Medical Dispensaries in Jacksonville Beach and Fernandina Beach | CURLF Stock News

StockTitan

Curaleaf Bolsters Florida Footprint with Two New Medical Dispensaries in Jacksonville Beach and Fernandina Beach | CURLF Stock News

CRLBF

Companies selling recreational marijuana in Illinois and Connecticut are facing lawsuits for allegedly failing to warn consumers about health risks associated with the drug. The lawsuits, filed on May 4, claim that cannabis can lead to serious health issues, including addiction and mental health disorders. Plaintiffs seek damages and clearer product warnings. The defendants, including Cresco and Curaleaf, deny the allegations, asserting compliance with state laws and regulations. The lawsuits highlight concerns over the marketing of marijuana products without adequate risk disclosures.

ZeroHedge

Cresco Labs Inc.

Marijuana Vendors Sued For Allegedly Not Warning Consumers Of Risks

Curaleaf Holdings, Inc. filed a Form 6-K with the SEC, reporting unaudited interim financials for Q1 2026. The filing includes financial statements as of March 31, 2026, and management's analysis, ensuring compliance and transparency. The latest analyst rating for CURA stock is a Buy with a C$5.50 price target, while Spark's AI Analyst rates it as Neutral, citing improving cash flow but weak underlying profitability. Curaleaf operates in the cannabis sector, registered with the SEC, and has a market cap of C$3.45B.

Curaleaf Files Q1 2026 Interim Financials on Form 6-K

A series of federal lawsuits have been filed against major cannabis companies, including Cresco Labs and Curaleaf, accusing them of misleading consumers about the medicinal benefits of their products. The lawsuits allege that these companies marketed cannabis as a treatment for various conditions despite knowing the scientific evidence was weak or nonexistent. Concurrently, the European Food Safety Authority has stated it cannot confirm the safety of CBD, while the U.S. government plans to include these products in Medicare without FDA approval, raising significant concerns about public health and safety.

MorningStar

Big Cannabis Sold You a Lie. Now the Federal Government Is Giving It to Your Grandparents.

SHOP

The TSX Composite Index fell 71.06 points to 33,566.91, influenced by a drop in Shopify shares, which fell 15.6%. TMX Group reported better-than-expected earnings, while Dream Impact Trust's losses widened. Health-care stocks rose, with Curaleaf and Bausch Health gaining. The TSX Venture Exchange also declined. In the U.S., stocks surged, with the Dow up 356.63 points and the NASDAQ hitting an all-time high. Oil prices dropped, while gold prices increased significantly. Overall, 85% of S&P 500 companies exceeded earnings expectations.

Curaleaf Holdings, Inc.(CURLF.US)

07:05 ETNew Global Cannabis Report from GCNC and Whitney Economics Examines How Pricing Compression Reshapes Emerging Markets

Curaleaf Replaces PKF O’Connor Davies with BDO USA as Independent Auditor

Curaleaf Holdings Opens Two New Stores in Florida

Curaleaf Bolsters Florida Footprint with Two New Medical Dispensaries in Jacksonville Beach and Fernandina Beach | CURLF Stock News

Marijuana Vendors Sued For Allegedly Not Warning Consumers Of Risks

Curaleaf Files Q1 2026 Interim Financials on Form 6-K

Big Cannabis Sold You a Lie. Now the Federal Government Is Giving It to Your Grandparents.

TSX Staggers by Tuesday Finish